Welcome to I Derm Pharma
Pioneering Innovation in Psoriasis Treatment
I Derm Pharma is revolutionizing the management of psoriasis with a first-in-class oral therapy targeting mild-to-severe cases. Based on a novel small molecule entity and an innovative mechanism of action, our approach offers a groundbreaking solution for patients suffering from autoimmune inflammatory skin diseases such as psoriasis.
The Problem
Psoriasis affects 2-3% of the global population, making it one of the most common and challenging autoimmune skin diseases. It is a chronic, painful, and often disabling condition that significantly impacts physical, functional, and emotional well-being.
Existing treatment options for moderate-to-mild patients, including oral therapies and biologics, have notable limitations:
- Oral therapies – Existing Oral therapies show limited efficacy or reduced safety, which can lead to severe side effects, toxicity, and require continuous monitoring.
- Biologics are effective but expensive, pose risks of long-term side effects, and their efficacy can diminish over time.
This underscores the unmet need for a new class of safe, effective, user-friendly, and cost-efficient oral treatments with a favorable tolerability profile.
Our Solution
At I Derm Pharma, we have developed a proprietary small molecule therapy that introduces a first-in-class mechanism of action. This groundbreaking approach targets a novel pathway within the local skin’s inflammatory pathway, effectively modulating inflammation without compromising the immune system.
Our oral solution combines enhanced safety, and low toxicity with high efficacy, offering the convenience of oral administration to address challenges associated with biologic injections.
The Market Opportunity
With one in 50 people globally affected by psoriasis, the demand for effective solutions continues to grow. As of 2023, the global psoriasis treatment market was valued at approximately USD 29.27 billion and is projected to reach USD 68.24 billion by 2033, exhibiting a CAGR of 8.9%.
I Derm Pharma is uniquely positioned to capture this growing market by addressing significant gaps in current therapies and providing a first-in-class solution for moderate-to-severe psoriasis patients.
Team:
Dr. Sharon Navon PhD, MBA, Co-Founder & CEO.
Sharon earned her Ph.D. from the chemistry faculty at the Technion. She has more than 8 years of experience in managing building & leading large pharmaceutical R&D teams for the development of peptide APIs. Sharon was responsible for the processes and the analytical package development, ensuring successful implementation at production sites to achieve GMP lots.
Prof. Eli Sprecher, MD, PhD, MBA, co-founder & clinical advisor.
Prof. Sprecher serves as the CEO of Tel Aviv Sourasky Medical Center. He is Frederick Reiss Professor of Dermatology at the Sackler Medical School, Tel Aviv University. Prof. Sprecher obtained his MD and PhD degrees from the Hebrew University of Jerusalem, and his MBA from Tel Aviv University. He underwent dermatology specialization at Rambam Medical Center and pursued a fellowship at Thomas Jefferson University, Philadelphia. Additionally, he serves as a section editor for the British Journal of Dermatology and is a board member of The European Society for Dermatological Research, along with being a member of the National Israeli Academy for Medical Sciences. Prof. Sprecher has authored over 300 peer-reviewed publications and has been honored with numerous national and international awards
Dr. Ofer Sarig, PhD, co-founder
Dr. Sarig is the Head of the Laboratory of Molecular Dermatology as part of the Division of Dermatology at the Tel Aviv Sourasky Medical Center. He earned both his MSc and PhD degrees from the Weizmann Institute of Science. With over 70 peer-reviewed publications and more than 20 presentations at scientific meetings, Dr. Sarig contributes significantly to dermatology research.
Zohar Gendler, M.Sc , Chairman of the Board
Zohar is managing Partner & CEO of NGT3 VC. Former CEO & director of Beta-O2 Technologies (developed proprietary implantable bio-artificial pancreas). Served as CEO of the Technion Technological Incubator for 11 years. Led the establishment and investment of more than 50 companies, such as Prolor Biotech (sold to OPKO, NYSE: OPK, for $480M), Mazor (NASDAQ: MZOR, sold to Medtronic, $1.6B), ReWalk (NASDAQ: RWLK), Corindus (NASDAQ: CVRS), Regentis, and many others.
Contact:
Sharon Navon (PhD, MBA), Co-Founder & CEO
052 7726521